Segments of Business and Geographic Areas (Details 1) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 30, 2014		Mar. 31, 2013
Segment Reporting Information [Line Items]
Research and Development in Process	$ 18		$ 64
Total Segment Operating Income	5,651		4,482
Percentage Change in Operating Income Loss Excluding Expenses Not Allocated to Segments	26.10%
Percentage Change in Operating Income Loss	27.30%
Less: Expense not allocated to segments	227	[1]	221	[1]
Earnings before provision for taxes on income	5,424		4,261
Consumer
Segment Reporting Information [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)
Gain (Loss) on Disposition of Other Assets	55
Total Segment Operating Income	479	[2]	547	[2]
Percentage Change in Operating Income Loss	(12.40%)
Pharmaceutical
Segment Reporting Information [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)
Litigation Expense			178
Research and Development in Process
Total Segment Operating Income	3,206	[3]	2,417	[3]
Percentage Change in Operating Income Loss	32.60%
Medical Devices and Diagnostics
Segment Reporting Information [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)
Litigation Expense			345
Integration transaction costs and currency related to a business acquisition	118		258
Product Liability Accrual, Period Expense
Research and Development in Process	18		64
Total Segment Operating Income	1,966	[4]	1,518	[4]
Percentage Change in Operating Income Loss	29.50%
Corporate and Other
Segment Reporting Information [Line Items]
Litigation Expense			$ 6

[1] Amounts not allocated to segments include interest income/(expense), noncontrolling interests and general corporate income/expense. The fiscal first quarter of 2013 includes litigation expense of $6 million.

[2] Includes a gain on the sale of intangible and other assets of $55 million recorded in the fiscal first quarter of 2013.

[3] Includes litigation expense of $178 million recorded in the fiscal first quarter of 2013.

[4] Includes Synthes integration/transaction costs of $118 million and an in-process research and development charge of $18 million recorded in the fiscal first quarter of 2014. Includes Synthes integration/transaction costs of $258 million, litigation expense of $345 million and an in-process research and development charge of $64 million in the fiscal first quarter of 2013.